SWItch/Sucrose Non-Fermentable (SWI/SNF) complex, originally discovered in yeast, functions 49 as the primary chromatin remodeler in humans during ontogeny and adult life 7 . It is a large (~2 50 MDa) evolutionarily conserved multi-functional complex that uses energy from ATP hydrolysis 51 to make nucleosomal DNA accessible for various regulatory proteins facilitating nuclear 52 processes such as transcription, DNA repair and maintenance of chromosomal stability 25 . The 53 multi subunit complex includes one of two ATPase subunits BRG1 or BRM, three core 54 components namely INI1, BAF155 (BRG1 Associated Factor) and BAF170, four mutually 55 exclusive DNA binding subunits namely the AT-rich interaction domain 1A (ARID1A or 56 BAF250a), ARID1B (BAF250b) 33 , ARID2 (BAF180) 34 or GLTSCR1/GLTSCR1L 21 , in addition 57 to up to ten varying accessory subunits. Inactivating mutations in genes encoding one of several 58 SWI/SNF subunits are identified in up to 20% of cancers 12 attesting to the importance of this 59 complex in tumor suppression. 60 61 ARID1B is a ubiquitously expressed subunit of the SWI/SNF complex 8 . ARID1B levels 62 increase during differentiation of embryonic stem cells 13 while its ectopic expression induces 63 TP53/CDKN1A causing cell cycle arrest in HeLa cells 9 suggesting a possible tumor suppressor 64 function. ARID1B loss of function events including mutations 6 , chromosomal rearrangements 26 65 and DNA methylation 14 are reported in several cancer types. In our previous study, we described 66 a tumor suppressor role for nuclear ARID1B in pancreatic cancer (PaCa) 14 . Here, we report 67 cytoplasmic localization of ARID1B in several pancreatic tumor samples that correlate 68 significantly with advanced tumor stage and lymph node positivity. Surprisingly, an NLS-mutant 69 version of ARID1B localized to the cytoplasm and stimulated RAF-ERK signaling and β-catenin 70 transcription activity causing increased tumorigenic features in pancreatic cancer cell lines as 71 well as in primary tumors. 72
73
Results 74
ARID1B exhibits cytoplasmic localization in PaCa 75
We previously reported loss of ARID1B expression in a significant proportion of PaCa samples 76 by immunohistochemistry (IHC) on a tissue microarray (TMA) 14 . We have now confirmed the 77 results on a larger TMA (figures 1a and S1; Table S1 ). A careful analysis surprisingly revealed 78 cytoplasmic localization of ARID1B in a significant proportion of tumor (but not normal) 79 samples confirmed independently by two pathologists blinded for the study (figures 1a-b; Table  80 S1). IHC performed on another nuclear protein (p53) did not reveal cytoplasmic stain in any 81 sample (data not shown) indicating that ARID1B cytoplasmic localization was not an artefact. 82
More importantly, ARID1B cytoplasmic localization correlated significantly with aggressive 83 clinical features including advanced tumor stage and lymph node positivity (figure 1c). We 84 therefore proceeded to test a possible role for cytoplasm localized ARID1B in PaCa progression. 85
86
ARID1B possesses a classical bipartite NLS sequence 87
In order to evaluate the significance of its cytoplasmic localization in pancreatic tumor samples 88 we decided to determine the effect of restricting ARID1B to the cytoplasm in PaCa cell lines. 89
Since this can be achieved by simply inactivating its NLS, we proceeded to define the ARID1B 90
NLS. 91 92
Based on a comparison of subcellular localization exhibited by several truncation constructs, the 93 probable location of the ARID1B NLS appeared to be between the ARID and the BAF250_C 94 domains (figure 2a; grey box). A computational search using cNLS mapper (http://nls-95 mapper.iab.keio.ac.jp) revealed several putative NLS sequences of which the one with the 96 highest score (Table S2) localized within the region (figure 2b) predicted by the truncation  97 constructs. This putative twenty one amino acid sequence appeared to belong to the classical 98 bipartite NLS family that is defined by two clusters of basic amino acids (Lysine-Arginine in this 99 case) separated by a spacer region of 9-12 amino acids (10 in this case). Sequence alignment of 100 human ARID1B (Uniprot ID: Q8NFD5) with its orthologues from 41 metazoan species (figure 101 S2a) followed by WebLogo based identification of the consensus (figure 2b) revealed significant 102 conservation of the predicted NLS. The ARID1B NLS was also significantly similar to that of its 103 paralog ARID1A (figure S2b). 104
105
Alanine substitutions in either one or both basic amino acid clusters caused ARID1B to be 106 significantly redistributed to the cytoplasm (figure 2c). Nuclear localization achieved through the 107 classical (mono or bipartite) NLS is regulated by the importin α/β pathway 16 . Importazole (an 108 importin β blocker 29 ) treatment caused a significant reduction in nuclear localization of 109 ectopically expressed as well as endogenous ARID1B (figures 2d and S3a) providing further 110 evidence towards the authenticity of the predicted NLS. Further, NLS peptides harboring 111 Alanine substitutions in either or both of the two basic amino acid clusters lost the ability of 112 nuclear translocation exhibited by the wild type NLS peptide (figures 2e and S3b). These results 113 suggest that the predicted NLS was not only necessary but perhaps sufficient to translocate an 114 unrelated protein into the nucleus. We confirmed ability of wild type ARID1B to cause reduction in cell viability and growth 9, 30 in 131 PaCa cells using crystal violet staining and MTT assay (figures 3d-e). Surprisingly however, the 132 cytoplasmic form of ARID1B appeared to exhibit a neo-morphic function causing a significant 133 increase in cell viability in the same assays (figures 3d-e). Further, cytoplasm localization of 134 ARID1B also caused an increased migratory potential in cells, while there was no effect upon 135 expression of the wild type 
Cytoplasm localized ARID1B activates RAF-ERK signaling 154
We performed a halo tag based pull down-mass spectrometry screen and surprisingly identified 155 components and regulators of the RAF-ERK signaling pathway including a-RAF and c-RAF as 156 potential interactors of cytoplasm-restricted ARID1B (Table S3 ). RAF-ERK signaling is a major 157 driver of cell viability and growth and is also shown to induce migratory phenotype in epithelial 158 cells 23 . Of note, previous studies have implicated the RAF-ERK signaling cascade in direct 159 phosphorylation of LRP6 leading to activation of canonical Wnt/β-catenin signaling 5 via 160 inhibition of CK1 mediated β-catenin phosphorylation 1 . 161
162
We confirmed ARID1B and c-RAF interaction by pull down followed by immunoblotting 163 (Table S3 ), the catalytic subunit of a protein 179 phosphatase known to dephosphorylate c-RAF at Ser259 11 . Using the pull down strategy 180 described in figure 4a we confirmed the interaction of cytoplasmic (but not nuclear) ARID1B 181 with PPP1CA ( figure 4d ). More importantly, the cytoplasmic (but not nuclear) version of 182 In order to obtain in vivo evidence for possible oncogenic function of cytoplasmic ARID1B, we 205 confirmed significantly increased tumor formation ability of MIA PaCa-2 cells expressing the 206 cytoplasmic form of ARID1B in nude mice xenograft experiments (figures 4h and S6a). We next 207 scrutinized the cBioPortal (cbioportal.org) cancer somatic mutation database and detected 208 several ARID1B mutations including splice site, frame shift and truncations that could 209 potentially inactivate the NLS. More importantly, we identified eight missense mutations located 210 within the NLS (Table S4 ). Of these, one (p.D1377N) was also detected in a PaCa sample (# 211 Panc43; Table S1) Table  225 S6) suggesting a wider clinical importance of our novel discovery. (Table S1 ) is depicted in red colour. List of 584 mutations is given in Table S4 
